At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 91 enrolled
Drug / intervention
Recombinant NDV Vectored Vaccine for SARS-CoV-2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Recombinant NDV Vectored Vaccine for SARS-CoV-2 for SARS-CoV-2 Infection. Completed, enrolled 91 participants across 1 site.
Detailed Summary
This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy volunteers at a single research site in Mexico City.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection
CountriesMexico
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartMay 2021
Primary CompletionAug 2022
Study CompletionSep 2022
TodayJul 2026
First PostedMay 4, 2021
Enrollment StartMay 20, 2021
Primary CompletionAug 21, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.2 years ago
Interventions
Recombinant NDV Vectored Vaccine for SARS-CoV-2biological
Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2